Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)
| Autor: | A. H. Maurer, H. W. Strauss, James T. Symanowski, P. R. Ellis, R. N. Joyrich, R. T. Morris, N. P. Shah, W. A. Harb, R. W. Naumann, J. M. Uszler |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Diagnostic Imaging medicine.medical_specialty Phases of clinical research Lesion chemistry.chemical_compound Folic Acid medicine Humans Folate Receptor 1 Molecular Targeted Therapy Vinca Alkaloids Aged Neoplasm Staging Ovarian Neoplasms Tomography Emission-Computed Single-Photon Vintafolide medicine.diagnostic_test business.industry Endometrial cancer Organotechnetium Compounds Hematology Middle Aged medicine.disease Radiography Clinical trial Oncology chemistry Folate receptor Response Evaluation Criteria in Solid Tumors Female Radiology medicine.symptom business Emission computed tomography |
| Zdroj: | Annals of Oncology. 25:852-858 |
| ISSN: | 0923-7534 0050-7741 |
| DOI: | 10.1093/annonc/mdu024 |
| Popis: | This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide).In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment. Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans. Single-photon emission computed tomography images of TLs were assessed for (99m)Tc-etarfolatide uptake as either FR positive or negative. Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%). Lesion and patient response were correlated with etarfolatide uptake.Forty-nine patients were enrolled; 43 were available for analysis. One hundred thirty-nine lesions were (99m)Tc-etarfolatide evaluable: 110 FR positive and 29 FR negative. Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P0.001). Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by (99m)Tc-etarfolatide imaging.NCT00507741. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|